Predictors and management of relapse to axicabtagene ciloleucel in patients with aggressive B-cell lymphoma.
Sign Up to like & getrecommendations! Published in 2021 at "Hematology/oncology and stem cell therapy"
DOI: 10.1016/j.hemonc.2021.09.001
Abstract: OBJECTIVE/BACKGROUND Despite the success of chimeric antigen receptor (CAR) T-cell therapy in patients with aggressive non-Hodgkin lymphoma (aNHL), some patients still fail treatment, and their prognosis is dismal. METHODS We performed a retrospective study of… read more here.
Keywords: axicabtagene ciloleucel; patients aggressive; axi cel; therapy ... See more keywords
Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2022.2096009
Abstract: ABSTRACT Introduction Axicabtagene ciloleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy that was recently approved for relapsed or refractory follicular lymphoma following progression on two or more lines of therapy including an… read more here.
Keywords: axicabtagene; relapsed refractory; follicular lymphoma; axicabtagene ciloleucel ... See more keywords
Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma
Sign Up to like & getrecommendations! Published in 2023 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2023.2177268
Abstract: ABSTRACT Introduction CD19-directed chimeric antigen receptor (CAR) T-cell therapy is a highly effective therapy for patients with relapsed/refractory large B-cell lymphoma (LBCL) and three CD19 CAR T-cell products (axicabtagene ciloleucel, tisagenlecleucel and lisocabtagene maraleucel) are… read more here.
Keywords: cell; safety; therapy; axicabtagene ciloleucel ... See more keywords
Impact of hypoalbuminemia on the prognosis of relapsed/refractory B‐cell lymphoma treated with axicabtagene ciloleucel
Sign Up to like & getrecommendations! Published in 2021 at "European Journal of Haematology"
DOI: 10.1111/ejh.13609
Abstract: Hypoalbuminemia is a known adverse prognostic factor in lymphomas. Yet, it is unknown if axicabtagene ciloleucel (axi‐cel) overcomes the adverse prognostic impact of hypoalbuminemia in relapsed/refractory large B‐cell lymphoma. read more here.
Keywords: axicabtagene ciloleucel; relapsed refractory; impact hypoalbuminemia; hypoalbuminemia ... See more keywords
Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas
Sign Up to like & getrecommendations! Published in 2020 at "Therapeutic Advances in Hematology"
DOI: 10.1177/2040620720902899
Abstract: Aggressive large B-cell lymphomas represent a diverse population of diseases that are typically treated with anti-CD20 based immunochemotherapy. While this treatment is effective for a large proportion of patients, those that become refractory to induction… read more here.
Keywords: axicabtagene ciloleucel; cell lymphomas; treatment; large cell ... See more keywords
5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1).
Sign Up to like & getrecommendations! Published in 2023 at "Blood"
DOI: 10.1182/blood.2022018893
Abstract: In phase 2 of ZUMA-1, a single-arm, multicenter, registrational trial, axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy demonstrated durable responses at 2 years in patients with refractory large B-cell lymphoma (LBCL).… read more here.
Keywords: cell; year; lymphoma; cell lymphoma ... See more keywords
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma.
Sign Up to like & getrecommendations! Published in 2020 at "Blood advances"
DOI: 10.1182/bloodadvances.2020001837
Abstract: The impact of bridging therapy (BT) administered between leukapheresis and chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL) is unclear. We evaluated the influence of BT (systemic therapy [ST], radiation therapy [RT],… read more here.
Keywords: axicabtagene ciloleucel; large cell; therapy; bridging therapy ... See more keywords
Circulating Tumor DNA Adds Specificity to PET following Axicabtagene Ciloleucel in Large B-cell Lymphoma.
Sign Up to like & getrecommendations! Published in 2023 at "Blood advances"
DOI: 10.1182/bloodadvances.2022009426
Abstract: We examined the meaning of metabolically active lesions on 1 month restaging nuclear imaging of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) receiving axicabtagene ciloleucel (axi-cel) by assessing the relationship between total metabolic tumor… read more here.
Keywords: cell; cell lymphoma; month; large cell ... See more keywords
Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma
Sign Up to like & getrecommendations! Published in 2020 at "Haematologica"
DOI: 10.3324/haematol.2020.254045
Abstract: Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 may be associated with long-term adverse effects such as cytopenia and immune deficiency. In order to characterize these late events, we analyzed 31 patients with relapsed or… read more here.
Keywords: axicabtagene ciloleucel; recovery; large cell; cell ... See more keywords
Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.698607
Abstract: Background Currently, three chimeric antigen receptor (CAR)-T cell products axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel have been approved by the U.S. Food and Drug Administration for the treatment of large B cell lymphoma, which provide… read more here.
Keywords: axicabtagene ciloleucel; lisocabtagene maraleucel; efficacy safety; treatment ... See more keywords
Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Tisagenlecleucel for the Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14030538
Abstract: Simple Summary CAR T therapies axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have been approved in Spain for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), given their favourable outcomes for overall survival and progression-free… read more here.
Keywords: tisa cel; axi cel; axicabtagene ciloleucel; cel ... See more keywords